Using LungVision navigation to place markers on ground-glass lung nodules before surgery
Official title: The LungVision Navigational Platform for Preoperative Labeling of Pulmonary Ground Glass Nodules With Fiducial Markers
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07180823 · Data updated 2026-11-12
This trial tests whether the LungVision augmented fluoroscopy system can place small fiducial markers during bronchoscopy to label partially solid ground-glass lung nodules in adults who are surgical candidates.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bologna) |
| Status | Recruiting |
| Started | July 21, 2025 |
| Main results expected | January 1, 2026 |
| Study ends | February 28, 2026 |
| Registry record updated | September 18, 2025 |
| Trial ID | NCT07180823 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with a partially solid peripheral pulmonary nodule having a solid component ≥6 mm or with documented growth, a bronchus sign or adjacent bronchus on chest CT, who can undergo bronchoscopy under deep sedation and are eligible for surgery.
✕Probably not a fit
Patients who cannot tolerate bronchoscopy or deep sedation, who are not surgical candidates, or who are pregnant will likely not benefit from this procedure.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study uses the LungVision augmented fluoroscopy navigation system combined with pre-procedure high-resolution CT and radial endobronchial ultrasound to guide bronchoscopy and place small fiducial markers into partially solid ground-glass pulmonary nodules. Markers are placed bronchoscopically under deep sedation so surgeons can more easily locate the lesion during subsequent minimally invasive surgery. The approach aims to reduce complications associated with percutaneous transthoracic marking, such as pneumothorax, and to enable smaller, tissue-sparing resections. Enrollment is at a single academic center in Bologna, Italy, with eligibility based on lesion size and presence of a bronchus sign on CT.
Why it matters
Potential benefit: If successful, this method could make it easier to locate and remove suspicious ground-glass nodules with smaller, lung-sparing surgeries while avoiding higher-risk transthoracic marking procedures.
How similar studies have gone: Early reports from a small number of studies using LungVision or similar augmented fluoroscopic navigation combined with radial EBUS have shown promising localization rates, but the overall evidence is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years; * Evidence of a partially solid peripheral pulmonary nodule with a solid component ≥ 6 mm or increasing in size, even if smaller, with a bronchus sign or adjacent bronchus on chest CT; * Obtaining the patient's informed consent. Exclusion Criteria: * Pregnancy or suspected pregnancy; * Contraindication to performing bronchoscopy under deep sedation, based on the anesthesiologist's assessment; * Patient not eligible for surgery due to high surgical risk, based on the anesthesiologist's assessment.
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy Recruiting
Study contacts
- Principal investigator: Piero Candoli, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Piero Candoli, MD
- Email: piero.candoli@aosp.bo.it
- Phone: +39 051 2145251
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.